Physical Injury As a Provoking Factor in Three Patients with Scleroderma

Total Page:16

File Type:pdf, Size:1020Kb

Physical Injury As a Provoking Factor in Three Patients with Scleroderma CASE REPORT Clinical and Experimental Rheumatology 2000; 18: 622-624. Physical injury as a ABSTRACT cirrhosis were found on ultrasound ex- A 51-year-old female developed linear- amination. provoking factor in like scleroderma in the left thigh In 1975, plaques characteristic of lichen three patients with following a linear wound caused by a ruber planus appeared on both buttocks car accident. 27 years later she also following several intramuscular injec- scleroderma developed a typical diffuse cutaneous tions. In 1983, symmetric polyarthralgia systemic sclerosis with extensive skin in the metacarpophalangeal and proxi- A. Komócsi, E. Tóvári, involvement and bibasilar pulmonary mal interphalangeal joint lines were de- 1 fibrosis. The second case is a 39-year- tected without any classical signs of in- J. Kovács , L. Czirják old female who had a history of flammation. A positive LE test, a homo- Raynaud’s phenomenon since early geneous antinuclear antibody staining Nephrological Center and 2nd Department childhood. She developed a morphea pattern (on rat liver section), and a mod- of Internal Medicine, University Medical following a burning injury of the left erately elevated Waaler-Rose titer were 1 School of Pécs, Pécs; Department of thigh. 17 years later she also devel- also found. In 1985, a bronchopneumo- Pathology, University Medical School of oped a typical limited cutaneous nia with a septic-toxic state was detected Debrecen, Debrecen; Hungary. systemic sclerosis with sclerodactyly, and cured. In the following years, apart András Komócsi, MD; Eszter Tóvári, MD; skin ulcers and subcutaneous calcino- from polyarthralgia, the patient was heal- Judit Kovács, MD, PhD; László Czirják MD, D.Sc. sis. The third case is a 43-year-old thy and asymptomatic. The local skin female who developed a typical involvement of the thigh remained sta- Please address correspondence and reprint morphea of the right elbow around the ble. Regarding the laboratory findings, requests to: Dr. László Czirják, University of Pécs, Medical Faculty, Nephrological site of a previous local corticosteroid a permanently elevated ESR (between Center and 2nd Department of Internal injection. The two remarkable points of 50-80 mm/hr) and a polyclonal increase Medicine, Clinical Immunology Unit, these 3 cases are the possible role of in the IgG level were detected. Pacsirta u. 1, H-7624 Pécs, Hungary. physical injury in the provocation of In 1990, skin symptoms characteristic of E-mail: [email protected] localized scleroderma and in the first 2 rapidly progressive diffuse cutaneous © Copyright CLINICAL AND cases the unusual later development of systemic sclerosis were detected, involv- EXPERIMENTAL RHEUMATOLOGY 2000. a systemic form of scleroderma. ing the trunk, face, and the extremities. The skin involvement which was histolo- Key words: Localized scleroderma, Introduction gically confirmed by a skin biopsy from systemic sclerosis, physical injury. Certain physical effects, including limb the forearm, was accompanied by exten- immobilization (1), spinal cord injury (2) sive hypo-hyperpigmentation and a bi- and radiation therapy (3, 4), may pro- basilar lung fibrosis with restrictive ven- voke scleroderma. Other forms of physi- tilatory failure. No other internal organ cal injury, including local injection, have involvement, myositis, or Raynaud’s also been described as possible provok- phenomenon were detected. No anti- ing factors of localized scleroderma (5- Borrelia, anti-Rnp, anti-topoisomerase I, 8). In the present study 3 patients are anti-centromere, and anti-nucleolar an- described who developed localized scle- tibodies were found. A homogeneous roderma following mechanical injury staining patter of antinuclear antibody (wound formation following a traffic (on HEp-2 cells) was found without the accident, thermal injury, and the effect presence of anti-dsDNA antibody. of a local injection). In 1990, a combination of D-penicilla- mine (300-450 mg/day), pentoxyfyllin Case histories (800 mg/day), and nifedipine (30 mg/ Case 1 day) therapy was introduced. The pro- A 51-year-old female patient suffered a gression of the skin symptoms stopped 20 cm longitudinal elongated wound, on 10 months later. The patient’s condition the left thigh during a traffic accident in became stable without any fluctuation in 1973. Six months following this local the following years. No signs of serious physical injury, a linear, scleroderma-like liver disease have been observed. lesion developed on the site of the former lesion. The histological investigation Case 2 proved the typical signs of scleroderma A 39-year-old female had a history of (Fig. 1). No other sites of the skin were Raynaud’s phenomenon involving sym- involved. The patient was a chronic al- metrically both hands since her early coholic with a possible intake of between childhood. In 1980, at the age of 21, she 10-50 g/day. No signs of liver or biliary spilt boiling water on the extensor sur- 622 Scleroderma and physical injury / A. Komócsi et al. CASE REPORT (a) (b) Fig. 1. (a) A linear scleroderma-like lesion at the site of a former elongated wound (Case 1). (b) Histological investigation demonstrated the typical signs of scleroderma with lymphocytic infiltrate around the eccrine glands (Case 1) (hematoxyllin and eosin staining, 160x). face of her left thigh. Months later a le- sclerodactyly. X-ray studies revealed a garding the investigation of the internal sion of typical morphea appeared in the subcutaneous calcinosis on the second organs, mild bibasilar lung fibrosis was affected area. Although the skin involve- phalanx of the left second finger and found on the chest x-ray and was con- ment was not confirmed by biopsy, the signs of mild bibasilar lung fibrosis. The firmed by high resolution computed to- lesion was described as morphea several latter was confirmed by high resolution mography. The latter did not show any times. In the following years the lesion computer tomography. No anticentro- signs suggesting the presence of alveo- became atrophic and some hypopigmen- mere antibody was detected. The find- litis. Spirometry values were normal ex- tation appeared and this condition re- ings described above were compatible cept a slightly diminished CO diffusion mained stable. In 1982, while the previ- with the development of limited cutane- coefficient. The antinuclear antibody test ous sites of morphea became more pro- ous systemic sclerosis. on HEp-2 cells was negative. nounced, the lower left quadrant of the abdominal skin became slightly hyper- Case 3 Discussion pigmented and indurated lesions appear- A 43-year-old female received a peri- Several provoking factors may contrib- ed. The abdominal skin was not previ- articular corticosteroid injection to the ute to the development of scleroderma. ously affected by the thermal injury. In lateral part of the right elbow in 1999, a We have previously described that ex- 1983 several tests were performed, in- few months before her first visit to our posure to certain chemicals including cluding: chest x-ray, barium swallow, department. The indication for the ad- organic solvents, are important provok- hand and feet x-rays, Schirmer’s test and ministration of this therapy remained ing agents of scleroderma among Hun- nailfold capillary microscopy. At that obscure; probably the presence of peri- garian cases (9). Regarding physical in- time none of the investigations or labo- ostitis was presumed. A few weeks later jury, limb immobilization (1), spinal cord ratory data showed any signs of systemic typical morphea (confirmed by biopsy) injury (2), and radiation therapy (3, 4), scleroderma. In 1986 a skin ulcer ap- was noticed around the site of the injec- have been reported as possible provok- peared over the left lateral ankle. Since tion (Fig. 2). No other sites of the body ing factors for scleroderma. All 3 patients that time repeated skin ulcers have ap- were affected. We did not detect joint described above also developed a local- peared in that area. Both the arterial and symptoms, and an x-ray of the right el- ized form of scleroderma (linear-like the venous circulation of this extremity bow did not show any abnormality. Re- scleroderma and morphea) following a were found to be normal. Since 1990 antinuclear antibody positi- vity was reported on rat liver sections. The antibody showed homogeneous nu- clear staining on HEp-2 cell cultures without anti-dsDNA positivity. Nailfold capillary microscopy described isolated apical widening of the capillary loops, but no abnormalities diagnostic of scle- roderma were detected. In 1997, the patient was admitted with complaints of Raynaud‘s phenomenon, slightly decreased maximal oral aperture, Fig. 2. Signs of morphea and facial teleangiectasia. The skin of the following a local cortico- fingers was tight, but not to the extent of steroid injection (case 3). 623 CASE REPORT Scleroderma and physical injury / A. Komócsi et al. local physical injury. scleroderma, but this seems to be a rather GARCIA A: Post-traumatic nodular scleroder- Our first case is unusual for diffuse scle- exceptional finding. ma. Med Cutan Ibero Lat Am 1983;11:329-32. roderma because, in spite of the exten- The vascular endothelial injury which is 7. ALONSO-LLAMAZARES J, AHMED I: Vitamin K1-induced localized scleroderma (morphea) sive skin involvement, a relative lack of a hallmark of scleroderma, may be me- with linear deposition of IgA in the basement internal organ manifestations was ob- diated by several mechanisms including membrane zone. J Am Acad Dermatol 1998; served. Such a physical injury as a pos- decreased endothelial expression of the 38: 322-4. sible provoking factor of scleroderma complement protective molecular sys- 8. BELLMAN B, BERMAN B: Localized indurated brown plaques on arms and right buttock. Pen- skin lesions has not been previously de- tem, white blood cell activation through tazocine-induced morphea. Arch Dermatol scribed. the production of free radicals, and fur- 1996; 132: 1366-7,1368-9. In the second patient the appearance of thermore an altered production of neuro- 9.
Recommended publications
  • Understanding and Managing Scleroderma
    Understanding and Managing Scleroderma A publication of Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 Maureen D. Mayes, M.D., M.P.H. Understanding and Understanding My notes and Managing Scleroderma Managing Scleroderma This booklet is intended to help people with scleroderma, their families and others interested ________________________ in learning more about the disease to better understand what scleroderma is, what effects ________________________ it may have, and what those with scleroderma can do to help themselves and their physicians ________________________ manage the disease. It answers some of the most frequently asked questions about ________________________ A publication of Maureen D. Mayes, M.D., M.P.H. Scleroderma Foundation 300 Rosewood Drive, Suite 105 scleroderma. Danvers, MA 01923 800-722-HOPE (4673) www.scleroderma.org www.facebook.com/sclerodermaUS www.twitter.com/scleroderma ________________________ Disclaimer The Scleroderma Foundation does not provide medical advice nor does it ________________________ endorse any drug or treatment mentioned herein. ________________________ The material contained in this booklet is presented for general information only. It is not intended to provide medical advice, to answer questions specific to the condition or problems of particular individuals, nor in ________________________ any way to substitute for the professional advice and care of qualified physicians. Mention of particular drugs and/or treatments is for ________________________ information purposes only and does not constitute an endorsement of said drugs and/or treatments. ________________________ Thanks! ________________________ The Scleroderma Foundation expresses its deep appreciation to the many ________________________ physicians whose efforts have led to this booklet. Special thanks are owed to Maureen D. Mayes, M.D., M.P.H., of the ________________________ University of Texas McGovern Medical School, Houston.
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Wound Classification
    Wound Classification Presented by Dr. Karen Zulkowski, D.N.S., RN Montana State University Welcome! Thank you for joining this webinar about how to assess and measure a wound. 2 A Little About Myself… • Associate professor at Montana State University • Executive editor of the Journal of the World Council of Enterstomal Therapists (JWCET) and WCET International Ostomy Guidelines (2014) • Editorial board member of Ostomy Wound Management and Advances in Skin and Wound Care • Legal consultant • Former NPUAP board member 3 Today We Will Talk About • How to assess a wound • How to measure a wound Please make a note of your questions. Your Quality Improvement (QI) Specialists will follow up with you after this webinar to address them. 4 Assessing and Measuring Wounds • You completed a skin assessment and found a wound. • Now you need to determine what type of wound you found. • If it is a pressure ulcer, you need to determine the stage. 5 Assessing and Measuring Wounds This is important because— • Each type of wound has a different etiology. • Treatment may be very different. However— • Not all wounds are clear cut. • The cause may be multifactoral. 6 Types of Wounds • Vascular (arterial, venous, and mixed) • Neuropathic (diabetic) • Moisture-associated dermatitis • Skin tear • Pressure ulcer 7 Mixed Etiologies Many wounds have mixed etiologies. • There may be both venous and arterial insufficiency. • There may be diabetes and pressure characteristics. 8 Moisture-Associated Skin Damage • Also called perineal dermatitis, diaper rash, incontinence-associated dermatitis (often confused with pressure ulcers) • An inflammation of the skin in the perineal area, on and between the buttocks, into the skin folds, and down the inner thighs • Scaling of the skin with papule and vesicle formation: – These may open, with “weeping” of the skin, which exacerbates skin damage.
    [Show full text]
  • Pressure Ulcer Staging Cards and Skin Inspection Opportunities.Indd
    Pressure Ulcer Staging Pressure Ulcer Staging Suspected Deep Tissue Injury (sDTI): Purple or maroon localized area of discolored Suspected Deep Tissue Injury (sDTI): Purple or maroon localized area of discolored intact skin or blood-fi lled blister due to damage of underlying soft tissue from pressure intact skin or blood-fi lled blister due to damage of underlying soft tissue from pressure and/or shear. The area may be preceded by tissue that is painful, fi rm, mushy, boggy, and/or shear. The area may be preceded by tissue that is painful, fi rm, mushy, boggy, warmer or cooler as compared to adjacent tissue. warmer or cooler as compared to adjacent tissue. Stage 1: Intact skin with non- Stage 1: Intact skin with non- blanchable redness of a localized blanchable redness of a localized area usually over a bony prominence. area usually over a bony prominence. Darkly pigmented skin may not have Darkly pigmented skin may not have visible blanching; its color may differ visible blanching; its color may differ from surrounding area. from surrounding area. Stage 2: Partial thickness loss of Stage 2: Partial thickness loss of dermis presenting as a shallow open dermis presenting as a shallow open ulcer with a red pink wound bed, ulcer with a red pink wound bed, without slough. May also present as without slough. May also present as an intact or open/ruptured serum- an intact or open/ruptured serum- fi lled blister. fi lled blister. Stage 3: Full thickness tissue loss. Stage 3: Full thickness tissue loss. Subcutaneous fat may be visible but Subcutaneous fat may be visible but bone, tendon or muscle are not exposed.
    [Show full text]
  • Pressure Ulcers By: Esther Hattler BS,RN,WCC
    Pressure Ulcers By: Esther Hattler BS,RN,WCC Staging Objectives The attendee will be able to list the 6 stages of pressure ulcers. Stage I Definition Intact skin with non-blanchable redness of a localized area usually over a bony prominence. Darkly pigmented skin may not have visible blanching. Its color may differ from surrounding area. Description Stage I The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. Stage I may be difficult to detect in individuals with dark skin tones. May indicate “at risk” persons (a heralding sign of risk). Pictures stage I Stage II Definition Partial thickness loss of dermis presenting as a shallow open ulcer with a red/pink wound bed, WITHOUT slough. May also present as an intact or open ruptured serum filled blister. Description stage II Presents as a shiny or dry shallow ulcer WITHOUT slough or bruising. The stage II should NOT be used to describe skin tears, tape burns, perineal dermatitis, maceration or excoriation. Pictures stage II Stage II Stage III Definition Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon, or muscle are not exposed. Slough may be present but does not obscure the depth of tissue loss. May include undermining and tunneling. Description stage III The depth of a a stage III pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have subcutaneous tissue and stage III ulcers can be shallow. In contrast, areas of significant adiposity can develop extremely deep stage III pressure ulcers.
    [Show full text]
  • A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute
    Index A Anti-EJ, 213, 214, 216 Acanthosis nigricans, 139 Anti-Ferc, 217 Acquired ichthyosis, 53, 126, 127, 159 Antigliadin antibodies, 336 Acute interstitial pneumonia (AIP), 79, 81 Antihistamines, 324 Adenocarcinoma, 115, 116, 151, 173 Anti-histidyl-tRNA-synthetase antibody Adenosine triphosphate (ATP), 229 (Anti-Jo-1), 6, 14, 140, 166, 183, Adhesion molecules, 225–226 213–216 Adrenal gland carcinoma, 115 Anti-histone antibodies (AHA), 174, 217 Age, 30–32, 157–159 Anti-Jo-1 antibody syndrome, 34, 129 Alanine aminotransferase (ALT, ALAT), 16, Anti-Ki-67 antibody, 247 128, 205, 207, 255 Anti-KJ antibodies, 216–217 Alanyl-tRNA synthetase, 216 Anti-KS, 82 Aldolase, 14, 16, 128, 129, 205, 207, 255, 257 Anti-Ku antibodies, 163, 165, 217 Aledronate, 325 Anti-Mas, 217 Algorithm, 256, 259 Anti-Mi-2 Allergic contact dermatitis, 261 antibody syndrome, 11, 129, 215 Alopecia, 62, 199, 290 antibodies, 6, 15, 129, 142, 212 Aluminum hydroxide, 325, 326 Anti-Myo 22/25 antibodies, 217 Alzheimer’s disease-related proteins, 190 Anti-Myosin scintigraphy, 230 Aminoacyl-tRNA synthetases, 151, 166, 182, Antineoplastic agents, 172 212, 215 Antineoplastic medicines, 169 Aminoquinolone antimalarials, 309–310, 323 Antinuclear antibody (ANA), 1, 141, 152, 171, Amyloid, 188–190 172, 174, 213, 217 Amyopathic DM, 6, 9, 29–30, 32–33, 36, 104, Anti-OJ, 213–214, 216 116, 117, 147–153 Anti-p155, 214–215 Amyotrophic lateral sclerosis, 263 Antiphospholipid syndrome (APS), 127, Antisynthetase syndrome, 11, 33–34, 81 130, 219 Anaphylaxi, 316 Anti-PL-7 antibody, 82, 214 Anasarca,
    [Show full text]
  • What's Inside: Become a Member Today!
    Texas Bluebonnet Chapter Newsletter Winter/Spring 2014 President’s Welcome Message Dear Partners in the fight against Scleroderma, It is hard to believe we are already looking at March! Time has gone by so quickly and we are in full swing of activity. Our Board for the Texas Chapter has some wonderful ideas and we have started to implement several of them. Over the next several months our Board Members will be visiting all of our Support Groups and we are looking forward to meeting all of you. Follow us on Face Book and our Website. Jasminne and Jacob are working to get our social media current and running smoothly. Fundraisers are already in the works with several walks, patient educations, dinners, rummage sales and disc golf tournaments. These are just a glimpse of some of the things we have coming this year. Stay tuned we have a lot more in store! - Audrey What's Inside: Become A Member Today! 1- Meet Your Board of Directors 2- Scleroderma Stories The Scleroderma Foundation TX Bluebonnet 3- The Doctor Is In-Finger Ulcers Chapter needs you! 5- Chapter News & Events Are you a member already? Do you receive the 7- Scleroderma Spotlight: Johns Scleroderma Voice? Do you need to renew Hopkins Study your annual membership? Not sure? Please go to our chapter page and sign up to become a member of the TX chapter today. Get Connected! Your membership keeps you up to date on chapter news and events and helps raise TX Chapter FB Page awareness and provide funds for research.
    [Show full text]
  • Oral Manifestations of Systemic and Cutaneous Lupus Erythematosus in a Venezuelan Population
    J Oral Pathol Med (2007) 36: 524–7 ª 2007 The Authors. Journal compilation ª Blackwell Munksgaard Æ All rights reserved doi: 10.1111/j.1600-0714.2007.00569.x www.blackwellmunksgaard.com/jopm Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population Jeaneth Lo´pez-Labady1, Mariana Villarroel-Dorrego2, Nieves Gonza´lez3, Ricardo Pe´rez3, Magdalena Mata de Henning1 1Dental School; 2Oral Medicine; 3Medical School, Universidad Central de Venezuela Caracas, Venezuela BACKGROUND: The aim of this study was to charac- and ⁄ or arthritis to renal failure or intense nervous, terize oral lesions in patients with systemic and cutane- cardiac and haematological disturbances (1). ous lupus erythematosus (LE) in a Venezuelan group. The basic manifestations of LE occur in the connect- METHODS: Ninety patients with LE were studied. Oral ive tissue and blood vessels, but depending on the biopsies were taken from patients who showed oral mu- anatomical location and course of the disease, LE has cosal involvement. Tissue samples were investigated with been classified as systemic LE (SLE) or cutaneous LE histology and direct immunofluorescence techniques for (CLE). Cutaneous lupus erythematosus includes variety the presence of immunoglobulins G, M, A and comple- of LE-specific skin lesions that are subdivided into three ment factor C3. categories: chronic CLE (CCLE), subacute CLE (SCLE) RESULTS: In 90 patients with LE, 10 patients showed oral and acute CLE (ACLE) based on clinical morphology lesions related to the disease. Sixteen lesions were and histopathologic examination (2–4). investigated. Oral ulcerations accompanied by white Patients with SLE frequently show cutaneous mani- irradiating striae occurred in five patients, erythema was festations during the course of the disease.
    [Show full text]
  • Healed Corneal Ulcer with Keloid Formation
    Saudi Journal of Ophthalmology (2012) 26, 245–248 Case Report Healed corneal ulcer with keloid formation ⇑ Hind M. Alkatan, MD a, ; Khalid M. Al-Arfaj, MD c; Mohammed Hantera, MD d; Soliman Al-Kharashi, MD b Abstract We are reporting a 34-year-old Arabic white female patient who presented with a white mass covering her left cornea following multiple ocular surgeries and healed corneal ulcer. The lesion obscured further view of the iris, pupil and lens. The patient under- went penetrating keratoplasty and the histopathologic study of the left corneal button showed epithelial hyperplasia, absent Bow- man’s layer and subepithelial fibrovascular proliferation. The histopathologic appearance was suggestive of a corneal keloid which was supported by further ultrastructural study. The corneal graft remained clear 6 months after surgery and the patient was sat- isfied with the visual outcome. Penetrating keratoplasty may be an effective surgical option for corneal keloids in young adult patients. Keywords: Corneal mass, Histopathology, Keloid, Penetrating keratoplasty Ó 2012 Saudi Ophthalmological Society, King Saud University. All rights reserved. doi:10.1016/j.sjopt.2011.10.005 Introduction segment has been often unsuccessful.7 In extreme cases, the eyes were eventually enucleated due to spontaneous corneal Keloids and hypertrophic scars are fibrous tissue out- perforation or buphthalmos.8 We describe a case of corneal growths that result from a deviation from normal wound- keloid after healed corneal ulcer which was successfully man- healing process and were first described in 1865.1 Clinically, aged by penetrating keratoplasty. The clinical, histopatho- corneal keloids appear as gray–white elevated masses dif- logic, and ultrastructural findings are all presented.
    [Show full text]
  • Beneath the Surface: Derm Clues to Underlying Disorders
    Christian R. Halvorson, MD; Richard Colgan, MD Department of Family and Beneath the surface: Derm clues Community Medicine, University of Maryland School of Medicine, Baltimore to underlying disorders [email protected] Dermatologic fi ndings are frequent indicators of The authors reported no potential confl ict of interest connective tissue disorders. Here’s what to look for. relevant to this article. any systemic conditions are accompanied by skin PRACTICE manifestations. Th is is especially true for connec- RECOMMENDATIONS Mtive tissue disorders, for which dermatologic fi nd- › When evaluating patients ings are often the key to diagnosis. with suspected cutaneous In this review, we describe the dermatologic fi ndings of lupus erythematosus, use some well-known connective tissue disorders. Th e text and multiple criteria—including photographs in the pages that follow will help you hone your histologic and immuno- diagnostic skills, leading to earlier treatment and, possibly, fl uorescent biopsy fi ndings better outcomes. and American College of Rheumatology criteria—to rule out systemic disease. C Lupus erythematosus: Cutaneous › Cancer screening with a and systemic disease often overlap careful history and physi- Lupus erythematosus (LE), a chronic, infl ammatory autoim- cal examination is recom- mended for all adult patients mune condition that primarily aff ects women in their 20s and whom you suspect of having 30s, may initially present as a systemic disease or in a purely dermatomyositis. C cutaneous form. However, most patients with systemic LE have some skin manifestations, and those with cutaneous › Suspect mixed connective LE often have—or subsequently develop—systemic involve- tissue disease in patients 1 with skin fi ndings charac- ment.
    [Show full text]
  • Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: a Review of the Literature
    Am J Clin Dermatol DOI 10.1007/s40257-017-0286-9 REVIEW ARTICLE Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature 1 3 2 Pongsawat Rodsaward • Titipong Prueksrisakul • Tawatchai Deekajorndech • 4 5,6 1 Steven W. Edwards • Michael W. Beresford • Direkrit Chiewchengchol Ó The Author(s) 2017. This article is an open access publication Abstract Oral ulcers are the most common mucosal sign in juvenile-onset systemic lupus erythematosus (JSLE). Key Points The ulcers are one of the key clinical features; however, the terminology of oral ulcers, especially in JSLE patients, is Oral ulcers are one of the key clinical features in often vague and ill-defined. In fact, there are several clin- juvenile-onset systemic lupus erythematosus (JSLE) ical manifestations of oral ulcers in JSLE, and some lesions patients; however, the terminology remains unclear. occur when the disease is active, indicating that early management of the disease should be started. Oral ulcers There are several oral ulcers in JSLE patients that are classified as lupus erythematosus (LE) specific, where sometimes go unnoticed, and some ulcers indicate the lesional biopsy shows a unique pattern of mucosal that treatment should be started promptly. change in LE, and LE nonspecific, where the ulcers and Lesional biopsy is required when other oral diseases their histopathological findings can be found in other oral cannot be excluded, such as oral lichen planus and diseases. Here, the clinical manifestations, diagnosis and oral lichenoid contact lesions. management of oral ulcers in JSLE patients are reviewed. 1 Introduction & Direkrit Chiewchengchol Juvenile-onset systemic lupus erythematosus (JSLE) is one [email protected] of the most common autoimmune diseases in children and has a clinical course ranging from mild, gradual onset to 1 Center of Excellence in Immunology and Immune-mediated Disease, Faculty of Medicine, Chulalongkorn University, rapid, progressive multi-organ failure [1].
    [Show full text]